IMPL - Impel Pharma reiterates possible Chapter 11 bankruptcy; down 23%
2023-08-18 11:45:16 ET
More on Impel NeuroPharma
- Impel Pharma Non-GAAP EPS of -$0.97 beats by $0.06, revenue of $5.01M misses by $0.24M
- Impel cut to Neutral at Wedbush on sales outlook for migraine therapy
- Impel stock rises as dosing begins in mid-stage trial of INP105 for agitation in autistic people
For further details see:
Impel Pharma reiterates possible Chapter 11 bankruptcy; down 23%